arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

ACHIEVE LIFE SCIENCES, INC.

ACHV
$6.65 ▲ +0.11 (+1.60%) at close
Healthcare ·In Vitro & In Vivo Diagnostic Substances ·USIn Vitro & In Vivo Diagnostic Substances
18 Visible periods
18 Metrics
Peer-ranked Benchmarks
Price Chart
18
Health
Poor
Bearish
auto_awesome

Analytical Summary

ACHIEVE LIFE SCIENCES, INC. faces fundamental challenges. The fundamentals warrant careful consideration of downside risks.

Market Cap $289.9M
Dividend Yield
Revenue Growth
Op. Margin
ROIC
FCF / Share $-1.13
Trailing P/E
Price / Book 16.5x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

18-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
Net Income Profit after all expenses
$-54.65M
↓ -37.2%
FCF / Share Free cash flow per share
$-1.13
↓ -22.2%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
1
Cash Quality
61

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 18 years · 67 quarters